(361.2) Levetiracetam as a Primary Agent

1. What is the mechanism of action of levetiracetam?
a. Binds and inhibits voltage-dependent Na+ channels
b. Binds to synaptic vesicle protein 2A
c. Binds and inhibits T-type Ca2+ channels
d. Binds to GABAA
e. None of the above
2. A common adverse effect of levetiracetam is:
a. Hypotension
b. Hepatotoxicity
c. Sedation
d. Eosinophilic pneumonitis
e. None of the above
3. When was levetiracetam FDA approved for the treatment of partial seizures in humans?
a. 1999
b. 2010
c. 1990
d. 2005
e. None of the above
4. Levetiracetam may be contraindicated in patients with:
a. Protein-losing enteropathy
b. Chronic kidney disease
c. Endocardiosis
d. Hepatic dysfunction
e. None of the above
5. Levetiracetam has high oral bioavailability with peak plasma concentrations occurring __________ after a single dose of the immediate release tablet?
a. 0.6 to 2.2 hours
b. 0.1 to 1 hour
c. 0.5 to 5 hours
d. 0.3 to 3 hours
e. None of the above
{"name":"(361.2) Levetiracetam as a Primary Agent", "url":"https://www.quiz-maker.com/QO1V6IONJ","txt":"1. What is the mechanism of action of levetiracetam?, 2. A common adverse effect of levetiracetam is:, 3. When was levetiracetam FDA approved for the treatment of partial seizures in humans?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by
Quiz Maker
Powered by: Quiz Maker